Compare Vaccine Stocks

Enter up to ten stock symbols separated by a comma or space (ex. GILD,JNJ,MRNA,NVAX,PFE).

NASDAQ:GILD NYSE:JNJ NASDAQ:MRNA NASDAQ:NVAX NYSE:PFE

Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFE Pfizer	$52.79 -2.3%	$54.89	$33.36 ▼ $61.71	$296.30B	0.69	37.95 million shs	41.06 million shs
MRNA Moderna	$160.07 -4.4%	$254.17	$117.34 ▼ $497.49	$64.90B	1.22	9.83 million shs	11.77 million shs
GILD Gilead Sciences	$68.51 +1.0%	$70.76	$61.39 ▼ $74.12	$85.94B	0.34	8.42 million shs	14.83 million shs
JNJ Johnson & Johnson	$164.87 -0.2%	$166.31	$151.47 ▼ $179.92	$434.04B	0.74	7.18 million shs	10.55 million shs
NVAX Novavax	$84.65 -6.3%	$161.55	$84.55 ▼ $331.68	$6.40B	1.17	6.37 million shs	5.72 million shs

MarketRank™

Company	Overall Score	Analyst's Opinion	Community Rank	Dividend Strength	Company Ownership	Earnings & Valuation
PFE Pfizer	3.50 of 5 Stars	2.3	4.8	4.2	2.5	3.8
MRNA Moderna	2.76 of 5 Stars	4.1	4.7	0.0	2.5	2.5
GILD Gilead Sciences	3.32 of 5 Stars	3.3	5.0	4.2	1.7	2.5
JNJ Johnson & Johnson	2.81 of 5 Stars	2.4	4.4	4.2	2.5	0.6
NVAX Novavax	2.13 of 5 Stars	3.4	5.0	0.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFE Pfizer	2.55	Buy	$57.42	8.77% Upside
MRNA Moderna	2.29	Hold	$247.63	54.70% Upside
GILD Gilead Sciences	2.57	Buy	$79.18	15.58% Upside
JNJ Johnson & Johnson	2.70	Buy	$187.40	13.67% Upside
NVAX Novavax	2.71	Buy	$245.83	190.41% Upside

Current Analyst Ratings

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
1/21/2022	MRNA Moderna	UBS Group	Initiated Coverage	Neutral	$221.00
1/21/2022	MRNA Moderna	Bank of America	Upgrade	Underperform ➝ Neutral	$135.00 ➝ $180.00
1/21/2022	NVAX Novavax	Cowen	Initiated Coverage	Outperform	$150.00
1/18/2022	MRNA Moderna	Morgan Stanley	Boost Price Target	Equal Weight	$313.00 ➝ $315.00
1/18/2022	GILD Gilead Sciences	Morgan Stanley	Lower Price Target	Equal Weight	$74.00 ➝ $72.00
1/14/2022	PFE Pfizer	BMO Capital Markets	Boost Price Target		$60.00 ➝ $76.00
1/14/2022	GILD Gilead Sciences	BMO Capital Markets	Initiated Coverage	Buy	$85.00
1/11/2022	PFE Pfizer	Barclays	Set Price Target		$54.00
1/10/2022	PFE Pfizer	The Goldman Sachs Group	Set Price Target		$51.00
1/7/2022	PFE Pfizer	Wells Fargo & Company	Boost Price Target	Overweight	$60.00 ➝ $65.00
1/6/2022	MRNA Moderna	Argus	Lower Price Target		$420.00 ➝ $350.00

(Data available from 1/22/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFE Pfizer	$41.91B	7.07	$2.99 per share	17.67	$11.42 per share	4.62
MRNA Moderna	$803.40M	80.78	N/A	N/A	$6.47 per share	24.74
GILD Gilead Sciences	$24.69B	3.48	$8.10 per share	8.46	$14.54 per share	4.71
JNJ Johnson & Johnson	$82.58B	5.26	$10.74 per share	15.35	$24.04 per share	6.86
NVAX Novavax	$475.60M	13.46	N/A	N/A	$9.85 per share	8.59

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFE Pfizer	$9.62B	$3.36	15.71	8.65	0.72	27.66%	30.70%	12.92%	2/8/2022 (Confirmed)
MRNA Moderna	-$747.06M	$16.31	9.81	6.18	0.25	59.69%	121.61%	49.46%	2/24/2022 (Estimated)
GILD Gilead Sciences	$123M	$5.86	11.69	10.12	0.71	26.91%	56.59%	16.36%	2/1/2022 (Confirmed)
JNJ Johnson & Johnson	$14.71B	$6.69	24.64	16.04	2.32	19.55%	37.90%	14.50%	1/25/2022 (Confirmed)
NVAX Novavax	-$418.26M	-$14.81	N/A	3.18	N/A	-89.31%	-149.66%	-45.23%	3/7/2022 (Estimated)

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/8/2022	N/A	PFE Pfizer	$0.88	N/A	-$0.88	N/A	N/A	N/A
2/1/2022	N/A	GILD Gilead Sciences	$1.47	N/A	-$1.47	N/A	N/A	N/A
1/25/2022	N/A	JNJ Johnson & Johnson	$2.12	N/A	-$2.12	N/A	N/A	N/A
11/4/2021	9/30/2021	MRNA Moderna	$9.49	$7.70	-$1.79	$7.70	$6.29 billion	$4.97 billion
11/4/2021	9/30/2021	NVAX Novavax	-$4.04	-$4.31	-$0.27	-$4.31	$347.34 million	$178.80 million
11/2/2021	9/30/2021	PFE Pfizer	$1.08	$1.34	+$0.26	$1.26	$22.82 billion	$24.09 billion
10/28/2021	9/30/2021	GILD Gilead Sciences	$1.72	$2.65	+$0.93	$3.25	$6.31 billion	$7.42 billion

(Earnings results data provided by Zacks Investment Research)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFE Pfizer	$1.56	2.96%	+14.71%	46.43%	12 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$2.84	4.15%	+24.56%	48.46%	6 Years
JNJ Johnson & Johnson	$4.24	2.57%	+18.36%	63.38%	60 Years
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/4/2022	JNJ Johnson & Johnson	quarterly	$1.06	2.47%	2/18/2022	2/22/2022	3/8/2022
12/10/2021	PFE Pfizer	quarterly	$0.40	3.05%	1/27/2022	1/28/2022	3/4/2022
10/28/2021	GILD Gilead Sciences	Quarterly	$0.71	4.38%	12/14/2021	12/15/2021	12/30/2021

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFE Pfizer	0.48	1.39	1.18
MRNA Moderna	0.02	1.35	1.25
GILD Gilead Sciences	1.22	1.37	1.20
JNJ Johnson & Johnson	0.43	1.34	1.11
NVAX Novavax	0.70	1.24	1.24

Ownership

Institutional Ownership

Company	Institutional Ownership
PFE Pfizer	64.88%
MRNA Moderna	59.11%
GILD Gilead Sciences	78.67%
JNJ Johnson & Johnson	67.48%
NVAX Novavax	48.62%

Insider Ownership

Company	Insider Ownership
PFE Pfizer	0.05%
MRNA Moderna	19.4%
GILD Gilead Sciences	0.12%
JNJ Johnson & Johnson	0.3%
NVAX Novavax	2.1%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PFE Pfizer	78,500	5.61 billion	5.61 billion	Optionable
MRNA Moderna	1,300	405.45 million	326.79 million	Optionable
GILD Gilead Sciences	13,600	1.25 billion	1.25 billion	Optionable
JNJ Johnson & Johnson	134,500	2.63 billion	2.62 billion	Optionable
NVAX Novavax	791	75.61 million	74.02 million	Optionable

ARAV, IMMP, ETTX, ELTP, and TLSA Headlines

Source	Headline
	My Kingdom for a Booster Shot: Hiccups Are Yet Another Vaccine Trial Hassle - MedPage Today medpagetoday.com - January 22 at 1:46 PM
	2 Growth Stocks That Could Take Off in February - Motley Fool fool.com - January 21 at 3:15 PM
	Why Novavax is the jab the unvaxxed have been waiting for - Gold Coast Bulletin goldcoastbulletin.com.au - January 21 at 3:15 PM
	Worldwide Adoption of Novavax Vaccines Makes It a Winner investorplace.com - January 21 at 3:01 PM
	Novavax (NASDAQ:NVAX) Receives New Coverage from Analysts at Cowen americanbankingnews.com - January 21 at 10:23 AM
	Novavax (NASDAQ:NVAX) Now Covered by Analysts at Cowen marketbeat.com - January 21 at 7:34 AM
	Novavax COVID-19 vaccine provisionally approved for use in Australia - SBS sbs.com.au - January 21 at 3:32 AM
	Novavax Stock is in a Tough Spot, but its Fortunes Could Improve investorplace.com - January 20 at 6:04 PM
	Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week - Nasdaq nasdaq.com - January 20 at 5:31 PM
	What difference will Novavax make in Australia's fight against COVID? - ABC News abc.net.au - January 20 at 5:31 PM
	Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week finance.yahoo.com - January 20 at 5:31 PM
	Novavax Is Oversold, Time To Buy for Future Growth investorplace.com - January 20 at 5:00 PM
	Novavax Is Worth 77% More Over the Next 2 Years investorplace.com - January 20 at 11:01 AM
	Why Novavax Stock Is Already Down 30% This Year forbes.com - January 20 at 8:48 AM
	Novavax Stock May Not Be This Cheap For Long investorplace.com - January 20 at 6:19 AM
	Novavax (NASDAQ:NVAX) Sets New 52-Week Low at $91.70 americanbankingnews.com - January 20 at 4:02 AM
	Novavax’s COVID-19 vaccine gains momentum with Australia approval - Fortune fortune.com - January 20 at 2:24 AM
	Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine - Kilgore News Herald kilgorenewsherald.com - January 19 at 9:24 PM
	TGA approves Novavax COVID vaccine, anti-viral pills to treat disease in vulnerable patients - ABC News abc.net.au - January 19 at 9:24 PM
	Could Novavax Go Parabolic? - Nasdaq nasdaq.com - January 19 at 11:23 AM
	Canada within 'weeks' of deciding on Novavax, Medicago vaccines - CTV News ctvnews.ca - January 18 at 6:12 PM
	Novavax (NASDAQ:NVAX) Shares Down 7.4% americanbankingnews.com - January 18 at 2:48 PM
	Here's Some Good News for Novavax That Investors Are Overlooking - Motley Fool fool.com - January 18 at 8:02 AM
	Here's Some Good News for Novavax That Investors Are Overlooking finance.yahoo.com - January 18 at 8:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.